tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Travere Therapeutics price target raised to $35 from $27 at Wells Fargo
PremiumThe FlyTravere Therapeutics price target raised to $35 from $27 at Wells Fargo
1M ago
Oracle surges on cloud outlook, Novo to cut 9,000 jobs: Morning Buzz
Premium
The Fly
Oracle surges on cloud outlook, Novo to cut 9,000 jobs: Morning Buzz
1M ago
Positive Outlook for Travere Therapeutics: Buy Rating Supported by FILSPARI’s Strong Data and Competitive Advantages
Premium
Ratings
Positive Outlook for Travere Therapeutics: Buy Rating Supported by FILSPARI’s Strong Data and Competitive Advantages
1M ago
Optimistic Outlook for Travere Therapeutics Driven by Regulatory Advancements and Market Opportunities
PremiumRatingsOptimistic Outlook for Travere Therapeutics Driven by Regulatory Advancements and Market Opportunities
1M ago
Nvidia reports Q2 beat, Snowflake posts ‘beat and raise’: Morning Buzz
Premium
The Fly
Nvidia reports Q2 beat, Snowflake posts ‘beat and raise’: Morning Buzz
1M ago
Ligand price target raised to $206 from $157 at H.C. Wainwright
Premium
The Fly
Ligand price target raised to $206 from $157 at H.C. Wainwright
1M ago
Positive Growth Outlook for Travere Therapeutics Driven by Filspari’s Market Potential and Strategic Initiatives
PremiumRatingsPositive Growth Outlook for Travere Therapeutics Driven by Filspari’s Market Potential and Strategic Initiatives
2M ago
Travere Therapeutics price target raised to $34 from $32 at Citi
Premium
The Fly
Travere Therapeutics price target raised to $34 from $32 at Citi
2M ago
Strong Sales Performance and Market Expansion Potential Drive Buy Rating for Travere Therapeutics
Premium
Ratings
Strong Sales Performance and Market Expansion Potential Drive Buy Rating for Travere Therapeutics
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100